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Abstract 
 
Introduction. While the route of estrogen administration is known to be an important 
determinant of the thrombotic risk among postmenopausal women using hormone 
therapy, recent data have shown that norpregnane derivatives but not micronized 
progesterone would increase venous thromboembolism risk among transdermal 
estrogens users. However, differential effects of progesterone and norpregnanes on 
haemostasis have not yet been investigated. 
Methods. We set up a cross-sectional study among healthy postmenopausal women 
aged 45 to 70 years. The impact of Activated Protein C (APC) on endogenous 
thrombin potential was investigated in plasma samples of 108 women who did not 
use any hormone therapy (n=40) or who were treated by transdermal estrogens 
combined with micronized progesterone (n=30) or norpregnane derivatives (n=38).  
Results. After exclusion of women with factor V Leiden and/or G20210A prothrombin 
gene mutations, there was no significant change in APC sensitivity among women 
who used transdermal estrogens combined with micronized progesterone compared 
to non-users. Women using transdermal estrogens combined with norpregnanes 
were less sensitive to APC than were non-users (p=0.003) or users of transdermal 
estrogens combined with micronized progesterone (p=0.004). In addition, 
prothrombin fragment 1+2 concentration was higher in users of transdermal 
estrogens plus norpregnanes than in non-users (p=0.004). Other haemostatic 
parameters did not vary significantly across the different subgroups. 
Conclusion. Transdermal estrogens combined with norpregnanes may induce an 
APC resistance and activate blood coagulation. These results provide a biological 
support to epidemiological data regarding the potential thrombogenic effects of 
norpregnanes. However, these findings need to be confirmed in a randomized trial.  
 
Key words: Activated Protein C resistance, Haemostasis, postmenopausal hormone 
therapy, progestogens 
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Introduction 
 
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary 
embolism, is one of the major harmful effects of hormone therapy use among 
postmenopausal women [1, 2]. Both observational studies and randomised clinical 
trials have shown that oral estrogens increased the risk of venous thromboembolism 
[3]. However, the ESTHER Study has recently suggested that transdermal estrogens 
might be safe with respect to thrombotic risk [4]. In addition, the type of progestogens 
might also be an important determinant of the thrombotic risk in women using 
combined estrogens [5]. In this case/control study, as well as in the E3N prospective 
cohort study, norpregnane derivatives, including nomegestrol acetate and 
promegestone could be thrombogenic. By contrast, micronized progesterone and 
pregnane derivatives were not associated with an increased thrombotic risk [5, 6]. 
Activated Protein C (APC) resistance, with or without associated with the presence of 
the factor V Leiden mutation, is a well established risk factor for venous 
thromboembolism [7, 8]. Randomized clinical trials have demonstrated that oral but 
not transdermal estrogens activated blood coagulation [9, 10] and induced an APC 
resistance state [10, 11], providing biological support to the differential association of 
oral and transdermal estrogens with VTE risk. However, whether or not the 
progestogen component of hormone therapy may play a role in haemostasis remains 
unclear. Therefore, we investigated the impact of micronised progesterone and 
norpregnane derivatives on haemostasis parameters in a cross sectional study 
among healthy postmenopausal women using transdermal estrogens.  
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Subjects and Methods 
 
Study design 
The SNAC (Study of NorpregnAnes on Coagulation) Study was a cross sectional 
study performed in France in a health care center (IPC, Paris) between 2006 and 
2007 among healthy postmenopausal volunteers women aged 45 to 70 years who 
did not use any hormone therapy or who were treated by transdermal estrogens 
combined with either micronized progesterone or norpregnane derivatives. 
Menopause was defined by amenorrhea for more than 12 months, bilateral 
ovariectomy, or hysterectomy and age older than 52 years. 
Exclusion criteria were anticoagulant treatment, personal history of thrombotic events 
(self-reported history of deep venous thrombosis or pulmonary embolism), arterial 
disease (self-reported history of myocardial infarction, coronary insufficiency, stroke, 
arterial occlusive disease) or cancer. 
Overall, we screened 1652 women who came voluntarily in the Health Care Center 
during the recruitment period. We excluded women who were not menopausal 
(n=654), women who were younger than 45 years or older than 70 years (n=201), 
women who presented an exclusion criteria (n=147) and women who used a 
hormone therapy different than transdermal estrogens combined with progesterone 
or norpregnanes (n=110). On the 540 reminding postmenopausal women (470 non-
users, 31 progesterone users and 39 norpregnanes users), 11 women, including 9 
non-users, 1 progesterone user and 1 norpregnanes user, refused to participate to 
the study (rate of 2 % similar between subgroups). The final sample consisted of 529 
subjects including women treated by transdermal estrogens combined with 
progesterone (n=30) or norpregnanes (n=38) and 461 non-users. Among the non-
users, one subject was randomly included as a control when we included one user. 
The final control sample consisted of 41 women. 
All participants answered a standardized questionnaire concerning their demographic 
background, medical history, drug use and personal habits such as smoking and 
alcohol consumption.  
Blood pressure was assessed three times on the right arm after 10-min rest. Height 
and weight of the subjects were systematically measured. Body mass index (BMI) 
was expressed as the ratio of the weight (kg) to the square of the height (m²). 
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Women were classified into several groups according to hormone therapy use and its 
type. Women who did not use any hormone therapy during the last 3 months were 
included as non-users. Current users had to be treated by hormone therapy at the 
time of blood sampling or to have interrupted their treatment less than 3 months prior. 
Treated women were included as users of transdermal estrogens combined with 
either micronized progesterone or norpregnane derivatives, including nomegestrol 
acetate and promegestone. Estrogens were exclusively 17-estradiol using at 50 µg 
daily dose. Women who were prescribed micronized progesterone took either 100 
mg per day during the entire month or 200 mg per day 12 days a month. 
Nomegestrol acetate or promegestone were used either during the entire month at 
the daily dose of 2.5 mg and 250 µg respectively, or 12 days a month at an average 
dose of 5 mg and 500 µg per day respectively. 
The study protocol was approved by an ethical committee. Written consent was 
obtained from all participants.  
 
Blood samples 
Venous blood was drawn between 08.00 h and 10.00 h after overnight fasting and 10 
min rest. Cholesterol, triglycerides and glucose measurements were performed 
immediately following blood sample. For coagulation measurements, venous blood 
(nine volumes) was collected in 5 mL vacutainer tubes containing 0.105 mol/L 
trisodium citrate (one volume). Platelet-poor plasma (PPP) was obtained by two 
centrifugation steps at 2500 g for 15 min at 15 °C. Small aliquots (400 µl) were 
transferred into plastic tubes, quickly frozen and stored at - 40 °C. Venous blood was 
also collected in tubes containing 0.084 mL 15% EDTA for DNA extraction. 
 
Haemostasis measurements 
Thrombin generation in the presence or absence of APC was measured according to 
the method described by Hemker et al. [12] on a Fluoroscan Ascent fluorometer 
(Thermolabsystems OY, Helsinki, Finland), using PPP reagent (a mixture of 
phospholipids (PL) and tissue factor (TF)), thrombin calibrator and fluorogenic 
substrate FluCa (Thrombinoscope BV, Maastricht, The Netherlands), mainly following 
the manufacturer’s instructions. Briefly, thrombin generation was triggered in 80µl 
citrated plasma by the addition of 20µl PPP reagent and 20µl of the fluorogenic 
substrate FluCa in the presence of 5µl APC 10µg/ml (Hyphen Biomed, Neuville 
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s/Oise, France) or 5µl NaCl 0.15M. Final concentration of PL and TF in the mixture 
was 3.9µM and 4.8pM respectively. Each thrombin generation measurement was 
calibrated against the fluorescence curve obtained under the same conditions except 
for PPP reagent which was replaced by a thrombin calibrator (Thrombinoscope BV). 
A pool of plasma samples from healthy subjects processed in the laboratory and 
stored frozen at -80°C was used to normalize the results. Inter-assay coefficients of 
variation calculated on the results obtained for the pool in 2 series of respectively 7 
and 6 independent runs were less than 10% for the concentration-dependent 
parameters (Endogenous Thrombin Potential (ETP) and peak height). 
For each plasma sample, a normalised APC sensitivity ratio (APCsrETP) was 
calculated by dividing the ratio of the ETP obtained in the presence of APC 
(ETP+APC) and in its absence (ETP-APC) by the ratio of the ETP+APC and ETP-APC 
determined in normal pooled plasma in the same experiment. A high APCsrETP 
indicates an APC resistance.  
Commercially available kits based on ELISA methods were used for measuring 
prothrombin fragment 1+2 (Enzygnost F1+2 micro, Behring), free Tissue Factor 
Pathway Inhibitor (TFPI) antigen (Asserachrom free TFPI, Stago) and Endothelial 
Protein C Receptor (EPCR) (Asserachrom EPCR, Stago). The other parameters 
(Factor VIII, fibrinogen, antithrombin (AT) activity, Protein S (PS) activity) were 
measured using reagents (FVIII deficient plasmas and Neoplastine, STA fibrinogen, 
STA Stachrom ATIII, STA Staclot PS) from Stago on a STAR analyser (Stago).  
 
DNA isolation and genotyping 
Genomic DNA was extracted from EDTA blood samples using a standard method. 
Screening for the FV Leiden mutation and the G20210A prothrombin mutation was 
performed as previously described [13]. 
 
Statistical analysis 
Based on a previous study [10], we estimated that 40 subjects per group were 
needed to detect a difference between groups of about two third SD for the rPCA 
distribution with a 5% two-sided level and a 80% statistical power.  
Distribution of each parameter was tested for normality. Mean levels are given in 
arithmetic form. Analysis of variance was used to compare the baseline 
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characteristics of the subjects. Multiple comparison procedures were used to assess 
the differences in haemostatic variables between users and non-users of hormone 
therapy. Bonferroni correction for multiple testing was applied and treatments were 
significantly different at the 0.05 level if there was a p value less then 0.016 within the 
subgroups. Stepwise multiple linear regression models were used to assess the 
relative contribution of the haemostatic variables to the prediction of APC sensitivity.  
All statistical analyses were performed with the Statistical analysis System (SAS) 
software, version 9.1(SAS Institute, Inc., Cary, NC, USA). 
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Results 
 
Table 1 shows the general characteristics of women according to hormone therapy 
use. Blood samples were obtained from 108 women, of whom 40 were non-users, 30 
used transdermal estrogens combined with micronized progesterone and 38 were 
treated by transdermal estrogens combined with norpregnane derivatives. A large 
majority of HT users were treated by gel (n=65) while only 5 women used a patch. 
Among users of transdermal estrogens combined with norpregnane derivatives, 23 
women were treated by nomegestrol acetate and 15 by promegestone.  
Overall, 9.3% of women were heterozygous for the factor V Leiden mutation or the 
20210 G>A prothrombin gene mutation and the repartition did not significantly differ 
between groups (p=0.38). Considering the known influence of these thrombogenic 
mutations on haemostasis, these women were excluded from the statistical analysis. 
Regarding the general characteristics of the subjects, no significant differences 
between the groups were found in terms of age, BMI, smoking status, blood pressure 
or lipidemia. Women who used transdermal estrogens combined with norpregnane 
derivatives were specifically prescribed these progestogens because of 
hyperestrogenic syndromes (breast tenderness (n=23) or uterus bleeding (n=12)). 
Parameters of thrombin generation according to hormone therapy use are given in 
the table 2. Inter-group differences were observed for APCsrETP, ETP+APC and Peak 
height+APC. While there was no significant change in APCsrETP between non-users 
and women using transdermal estrogens combined with micronized progesterone, 
women who used transdermal estrogens combined with norpregnane derivatives 
were significantly less sensitive to APC than both non-users and users of transdermal 
estrogens combined with micronized progesterone (p<0.01). In addition, the 
norpregnanes-treated group had borderline significant higher levels of ETP+APC and 
Peak height+APC compared to the two other groups (p<0.05 for both ETP+APC and 
Peak height+APC). This pattern reflected the individual correlation of ETP+APC and 
Peak height+APC with APCsrETP (r=0.77, p<0.0001 for ETPAPC and r=0.75, p<0.0001 
for peak height+APC) and the strong correlation between peak height+APC and ETPAPC 
(r=0.97, p<0.0001). Other parameters of thrombin generation did not differ across the 
different groups.  
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The Table 3 shows the results for others haemostatic parameters measurements 
according to the hormone therapy use. Women treated by transdermal estrogens 
combined with norpregnane derivatives had an increased mean value of prothrombin 
activation peptide (F1+2) compared to non-users (p<0.01). Other haemostatic 
parameters, especially PS activity and free TFPI, did not vary significantly across the 
different subgroups.  
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Discussion 
 
Our results showed the importance of the progestogen component in determining the 
APC resistance state among postmenopausal women using transdermal estrogens. 
While micronized progesterone did not affect haemostasis, norpregnane derivatives 
might induce APC resistance and might activate blood coagulation. These data 
provide a biological support to the recent findings regarding the increased risk of 
venous thrombosis among postmenopausal women using transdermal estrogens 
combined with norpregnane derivatives [5, 6].   
 
The effect of progestogens on VTE risk remains largely unknown among 
postmenopausal women using hormone therapy. However, randomised clinical trials, 
as well as observational studies, provided some evidence for a more thrombogenic 
tendency of estrogens associated with progestogens compared to estrogens alone 
[3, 14-16]. In the Women’s Health Initiative (WHI) Clinical trials as well as in the 
Women’s International Study of long Duration Oestrogen after Menopause 
(WISDOM) trial, there was an increased VTE risk among women receiving opposed 
estrogens compared with the users of estrogen only. Data regarding the differential 
association of VTE risk with type of progestogens remain scarce and only two 
observational studies have so far assessed the thrombotic risk associated with the 
different pharmacological subgroups of progestogens [5, 6]. Taking into account the 
difficulties to obtain new clinical data for studying the effect of progestogens on 
thrombotic risk, assessing their impact on surrogate markers of VTE risk may 
therefore be useful. In addition, APC resistance has been shown to be a valid marker 
of VTE risk [17]. Since transdermal estrogens have no or little effect on haemostasis 
[11, 18-21], assessment of progestogens on blood coagulation appears to be more 
relevant among postmenopausal women using transdermal estrogen therapy. 
Previous observational studies and randomised controlled trials have investigated the 
effect of transdermal estrogens in combination with micronized progesterone [9, 10], 
medroxyprogesterone acetate [22-24] or nortestosterone derivatives [25-27]. In the 
randomised controlled trials, transdermal estrogens combined with micronized 
progesterone did not have an effect either on APC resistance or on prothrombin 
fragment 1+2 concentration [9, 10] and the present findings are consistent with this 
previous results. One randomised study showed an increase in prothrombin fragment 
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1+2 concentration among users of transdermal estrogens combined with 
medroxyprogesterone [22]. In another trial, nortestosterone derivatives used in 
transdermal estrogen therapy had little or no effect on blood coagulation activation 
and haemostasis [25-27]. No data are currently available on the effects of 
norpregnane derivatives on haemostasis among transdermal estrogens users. 
However, some studies have investigated their impact in association with oral 
estrogen therapy among postmenopausal women. While studies have thus far failed 
to show any changes in levels of haemostatic parameters between norpregnane 
derivatives and dydrogesterone users [28-30], recent data suggested that 
trimegestone, a norpregnane derivative, could have a stronger impact on fibrinolysis 
compared to dydrogesterone [31].  
 
The mechanisms underlying the effects of transdermal estrogens combined with 
norpregnane derivatives on haemostasis remain unclear. It has been reported that 
changes in free PS and TFPI might have important roles in determining the sensitivity 
of plasma to APC in women receiving oral estrogens [10, 11, 32]. We have previously 
described no influence of transdermal estrogens combined with micronized 
progesterone on these parameters [10, 33]. However, whether or not transdermal 
estrogens plus norpregnane derivatives have a significant influence on these factors 
remains unknown. In the present study, the reduced APC sensitivity observed in 
women using transdermal estrogens combined with norpregnane derivatives was not 
mediated by PS or free TFPI, the levels of which were not significantly different from 
those observed among non-users and among users of transdermal estrogens 
combined with micronized progesterone. We have also measured plasma levels of 
the soluble form of EPCR which was previously reported to inhibit APC anticoagulant 
activity [34] and might therefore be a candidate to explain differences in APC 
resistance level. However, no significant inter-group differences have been observed. 
Future research will therefore be necessary to explain the influence of norpregnane 
derivatives on APC resistance.  
 
The SNAC Study is an observational study and we cannot exclude the possibility that 
these findings may be due in part to bias, especially selection bias. Norpregnane 
derivatives, either nomegestrol acetate or promegestone, are potent progestogens 
which have both high antiestrogenic and antigonadotrophic actions. Thus, these 
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progestogens may oppose the estrogen proliferation effect. Norpregnane derivatives 
are therefore preferentially prescribed to women with hyperestrogenic symptoms 
(endometrial susceptibility, benign breast diseases, …) [35-37]. Since endogenous 
estrogens exposure has been positively related to VTE among postmenopausal 
women [38], women with stronger estrogenic climate would be more likely to be at 
high thrombotic risk. As a consequence, we cannot exclude the possibility that APC 
resistance - which is observed among women using norpregnane derivatives - might 
also be related to a hypercoagulability state due to the presence of a hyperestrogenic 
status rather than exclusively to the deleterious effect of these progestogens on 
haemostasis. Therefore, this bias could in part explain the increased level of blood 
coagulation activation and APC resistance among users of norpregnane derivatives. 
Another selection bias could also occur among users of progesterone which is 
preferentially used by obese women because of its neutral impact on cardiovascular 
risk factors. However, in our study, women using progesterone had a similar average 
BMI than control women and means of haemostatic parameters were adjusted for 
BMI. Finally, a limitation of our study relates to the extrapolation of results. Our data 
on norpregnanes were restricted to nomegestrol acetate and promegestone and the 
results cannot be extrapolated to others norpregnane derivatives, including 
trimegestone. 
 
Conclusion 
 
Our results emphasize the importance of the progestogen components in hormone 
therapy on plasma sensitivity to APC resistance and other haemostatic variables. 
They may serve to provide a biological support to the differences in thrombotic risk by 
different progestogens variety. Taken together, both clinical [4, 5] and biological data 
[9, 10] suggest that transdermal estrogens combined with micronized progesterone 
might be safe with respect to thrombotic risk. However, these findings need to be 
confirmed in randomized controlled trials. 
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Tables 
 
Table 1: General characteristics of women according to hormone therapy 
 
No hormone therapy  
(n=40) 
Transdermal estrogens 
+ progesterone (n=30) 
Transdermal estrogens + 
norpregnanes# (n=38) 
Age (years) 59.5 (5.8) 58.4 (6.1) 58.7 (5.8) 
Body-mass index (kg/m²) 24.3 (3.9) 23.3 (2.2) 23.4 (4.1) 
Waist/Hip ratio 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 
Natural menopause 39 (98) 30 (100) 37 (97) 
Smoking status 
   Never users 
   Past users 
   Current users 
 
24 (60.0) 
11 (28.0) 
  5 (12.0) 
 
12  (40.0) 
12  (40.0) 
  6  (20.0) 
 
22 (58.0) 
13 (34.0) 
  3 (8.0) 
Systolic pressure (mmHg) 125.7 (20.4) 120.6 (16.4) 132.2 (24.2)  
Diastolic pressure (mmHg) 74.2 (11.2) 71.2 (9.3) 74.6 (12.5)  
Cholesterol (mg/dl) 230.1 (30.8)  223.7 (31.6) 217.9 (31.3)  
HDL (mg/dl) 68.7 (15.4) 69.7 (15.7) 71.9 (15.3) 
Triglyceride (mg/dl) 80.5 (28.1) 80.0 (36.9) 74.7 (39.8) 
FV Leiden mutation 2 (5.0) 1 (3.5) 2 (5.4) 
FII 20210 G>A mutation 2 (5.0) 0 (0) 3 (8.1) 
Values are mean (SD) or number (percentages) 
* Women received either nomegestrol acetate (n=23) or promegestone (n=15) 
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Table 2: Parameters of thrombin generation according to hormone therapy  
 
No hormone therapy  
(n=36) 
Transdermal estrogens 
+ progesterone (n=29) 
Transdermal estrogens + 
norpregnanes (n=33)# 
Lag Time-APC (min) 2.02 (0.38) 1.92 (0.59) 1.79 (0.41) 
Lag Time+APC (min) 
 
2.44 (0.77) 2.64 (0.65) 2.82 (0.63) 
Peak height-APC (nM IIa) 
 
280.42 (22.71) 281.21 (28.59) 280.61 (27.38) 
Peak height+APC (nM IIa)  16.15 (14.47) 15.03 (13.63)  23.79 (18.84) * 
£ 
ETP-APC (nM/min) 1639 (158) 1668 (196) 1693 (188) 
ETP+APC (nM/min) 134 (102) 133 (104)  197 (132) * 
£ 
APCsrETP 1.00 (0.63) 0.98 (0.72)  1.64 (1.17) ** 
££ 
Mean values (SD) adjusted for age and body-mass index 
# Women received either nomegestrol acetate (n=19) or promegestone (n=14) 
 
Comparison to non-user group: * p<0.05; ** p<0.01 
Comparison to the group treated by transdermal estrogens combined with micronized 
progesterone: £ p<0.05; ££ p<0.01  
 
 
Table 3: Haemostatic characteristics according to hormone therapy  
 
No hormone therapy  
(n=36) 
Transdermal estrogens 
+ progesterone (n=29) 
Transdermal estrogens + 
norpregnanes# (n=33) 
Antithrombin (%) 
 
103.4 (7.7) 
 
100.0 (6.1) 
 
104.4 (7.6)  
Protein S (%) 
 
 
103.9 (16.8)  
 
105.9 (16.9) 
 
104.7 (23.6) 
 Fibrinogen (g/L) 
 
3.3 (0.6) 
 
3.4 (0.6)  
 
3.1 (0.6)  
 TFPI (ng/mL) 
 
10.1 (5.0) 
 
8.8 (3.2)  
 
8.8 (4.5) 
 F1+2 (pmol/L) 253.9 (88.8) 
 
284.9 (93.7) 
 
330.0 (129.3) * 
Factor VIII (%) 
 
108.3 (38.3) 
 
91.4 (32.3) 
 
99.0 (25.4) 
 sEPCR (ng/ml) 126.44 (96.70) 130.66 (83.22) 101.48 (54.62) 
Mean values (SD) adjusted for age and body-mass index 
# Women received either nomegestrol acetate (n=19) or promegestone (n=14) 
Comparison to non-user group: * p<0.01 
 
 
